GlassScriptPhysician profile
Jean B Cain
NPI 1558404319
$214,192.31
in general payments reported to CMS, 2019-2025
14 companies · $41K in 2025
The $41K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31K · 2022: $40K · 2023: $44K · 2024: $57K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Travel and Lodging: $26K · Consulting Fee: $13K · Honoraria: $9,560 · Food and Beverage: $5,874 · Education: $19.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,290.00 |
| Travel and Lodging | $25,784.47 |
| Consulting Fee | $13,067.25 |
| Honoraria | $9,560.00 |
| Food and Beverage | $5,874.25 |
| Education | $19.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $102,199.96 | 2021-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $20,677.18 | 2021-2024 | Vumerity, Tysabri, Tysabri |
| Tg Therapeutics, INC. | $20,327.40 | 2023-2025 | Briumvi |
| Horizon Therapeutics Plc | $13,682.25 | 2022-2023 | Uplizna, Tepezza |
| Amgen INC. | $12,357.06 | 2024-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $11,592.94 | 2021-2025 | Ultomiris, Soliris |
| Janssen Pharmaceuticals, INC | $11,035.79 | 2021-2022 | |
| Genentech USA, INC. | $8,032.36 | 2021-2025 | Ocrevus |
| E.R. Squibb & Sons, L.L.C. | $6,909.62 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $3,756.18 | 2021-2025 | Kesimpta |
| Celgene Corporation | $3,535.54 | 2021-2025 | Zeposia |
| Genentech, INC. | $32.61 | 2021 | |
| Mylan Specialty L.P. | $27.82 | 2023 | Glatiramer Acetate |
| Genzyme Corporation | $25.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.